ライフサイエンスコーパス: clarithromycin

1 roton pump inhibitor (PPI), amoxicillin, and clarithromycin.

2 ed to serum after systemic administration of clarithromycin.

3 ulosis has intrinsic inducible resistance to clarithromycin.

4 loid cells possess a similar transporter for clarithromycin.

5 a transporter that takes up and concentrates clarithromycin.

6 tured HL-60 cells were incubated with [(3)H]-clarithromycin.

7 Mycobacterium avium complex isolates against clarithromycin.

8 ombining colchicine with medications such as clarithromycin.

9 and SCC-25 cells were incubated with [(3)H]-clarithromycin.

10 tibiotics as erthyromycin, azithromycin, and clarithromycin.

11 dilution for the detection of resistance to clarithromycin.

12 lithromycin, a ketolide that is derived from clarithromycin.

13 eration cephalosporins, and azithromycin and clarithromycin.

14 quinolones and sulfonamides but resistant to clarithromycin.

15 the disk diffusion test with ampicillin and clarithromycin.

16 AC isolates, respectively, were resistant to clarithromycin.

17 for the rest), followed by ciprofloxacin and clarithromycin.

18 5%) by microdilution but were not found with clarithromycin.

19 were the parent macrolides azithromycin and clarithromycin.

20 he related outcome for patients treated with clarithromycin.

21 acterium to antimicrobial agents, especially Clarithromycin.

22 ting mutations associated with resistance to clarithromycin.

23 he isolates were susceptible to amikacin and clarithromycin.

24 igilance, improved during a 2-week course of clarithromycin.

25 h hypotension (111 patients of 96,226 taking clarithromycin [0.12%] vs 68 patients of 94,083 taking a

26 kidney injury (420 patients of 96,226 taking clarithromycin [0.44%] vs 208 patients of 94,083 taking

27 ee antibiotics (ciprofloxacin ~0.0067 mg/ml, clarithromycin ~0.05 mg/ml, rifampicin ~0.002 mg/ml) cou

28 use mortality (984 patients of 96,226 taking clarithromycin [1.02%] vs 555 patients of 94,083 taking

29 n, 2 microg/ml; Bay y 3118, 0.015 microg/ml; clarithromycin, 1.25 microg/ml; D-cycloserine, 25 microg

30 The 26 isolates were susceptible to clarithromycin (100%), rifabutin (100%), ethambutol (92%

31 e the following: amikacin (14/16; 87.5%) and clarithromycin (12/16, 75.0%).

32 ility of fully oral rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extended release once daily for

33 target ratios for ethambutol, versus 42% for clarithromycin, 19% for amikacin, 18% for rifampicin, an

34 assigned active treatment (omeprazole 20 mg, clarithromycin 250 mg, and tinidazole 500 mg, each twice

35 ylori resistance were 17% (95% CI 15-18) for clarithromycin, 44% (95% CI 39-48) for metronidazole, 18

36 examined with PMNs loaded by incubation with clarithromycin (5 mug/ml).

37 g bid for 5 days and Proton-Pump Inhibitor + Clarithromycin 500 mg + Metronidazole/Tinidazole 500 mg

38 ients were given dexamethasone 40 mg weekly, clarithromycin 500 mg twice daily, and lenalidomide 25 m

39 hasone (40 mg) was given orally once weekly, clarithromycin (500 mg) was given orally twice daily, an

40 ) amoxicillin, 750 mg three times daily, and clarithromycin, 500 mg three times daily; 2)tetracycline

41 2)tetracycline, 500 mg four times daily, and clarithromycin, 500 mg three times daily; or 3) tetracyc

42 ter, subjects were administered six doses of clarithromycin, 500 mg, every 12 hours.

43 controlled, double-blind, crossover trial of clarithromycin 500mg with breakfast and lunch, in patien

44 e frequent for ethambutol (48% of patients); clarithromycin (56%); and azithromycin (35%).

45 Therapy with clarithromycin, a compound commonly used to treat MAC di

46 Clarithromycin accumulates in phagocytes, monocytes, fib

47 It is feasible that clarithromycin accumulation inside PMNs could enhance th

48 [(14)C]-clarithromycin accumulation was 2.2-fold higher in RPMI

49 ide [PAbetaN], an efflux inhibitor), [(14)C]-clarithromycin accumulation, azithromycin-induced protei

50 Although clarithromycin administered daily resulted in a reductio

51 this system may enhance the effectiveness of clarithromycin against invasive periodontal pathogens.

52 4 mug/mL decreased the MIC of rifampicin and clarithromycin against the same pathogens from 16 to 32

53 Pharmacodynamic indices for rifampicin, clarithromycin, amikacin, and moxifloxacin are seldom me

54 The isolates were susceptible to clarithromycin, amikacin, and rifabutin, while resistanc

55 Antibiotic activity was tested for clarithromycin, amikacin, cefoxitin, tigecycline, and be

56 Clarithromycin, amoxicillin, and a pump proton inhibitor

57 ting of H. pylori isolates to metronidazole, clarithromycin, amoxicillin, and tetracycline was perfor

58 amoxicillin, twice daily for 14 days; 500 mg clarithromycin and 500 mg nitroimidazole were added, twi

59 days, followed by 40 mg pantoprazole, 500 mg clarithromycin and 500 mg tinidazole, twice daily for th

60 ound to have H. pylori isolates resistant to clarithromycin and 83 (66%) were found to have H. pylori

61 nd reduced bacillary loads in spleen whereas clarithromycin and amikacin prevented death but had litt

62 M. abscessus (sub)species and for detecting clarithromycin and amikacin resistance mutations and tha

63 g, whereas performance in rapid detection of clarithromycin and amikacin resistance was evaluated by

64 ium abscessus subspecies and for determining clarithromycin and amikacin resistance.

65 nce of two major therapeutic antimicrobials, clarithromycin and amikacin.

66 six macrolide resistant) were tested against clarithromycin and azithromycin (the latter only by BACT

67 The oral macrolides clarithromycin and azithromycin are commonly used for tr

68 easured baseline characteristics between the clarithromycin and azithromycin groups.

69 Macrolides, such as clarithromycin and azithromycin, possess antimicrobial,

70 Clarithromycin and combination therapy were more effecti

71 uded intermediate ciprofloxacin MICs but low clarithromycin and doxycycline MICs of < or =1 microg/ml

72 Isolates were universally resistant to clarithromycin and doxycycline.

73 Clarithromycin and erythromycin, but not azithromycin, i

74 t commonly prescribed antibiotic regimen was clarithromycin and ethambutol.

75 le the alleles associated with resistance to clarithromycin and levofloxacin have been defined, there

76 support the use of WGS for the detection of clarithromycin and levofloxacin resistance.

77 Prevalence of resistance to clarithromycin and levofloxacin rose significantly over

78 Our aim was to compare the efficacy of Clarithromycin and Levofloxacin-based sequential quadrup

79 ts with H pylori infections in areas of high clarithromycin and metronidazole resistance.

80 Other amoxicillin alternatives, clarithromycin and metronidazole, while significantly wo

81 ternative drugs in the same class, including clarithromycin and moxifloxacin, were unknown.

82 time was not significantly different between clarithromycin and placebo.

83 eceived treatment consisting of amoxicillin, clarithromycin and PPI (AC/PPI).

84 The efficacy and safety of clarithromycin and rifabutin alone and in combination fo

85 MICs, producing nearly twofold increases for clarithromycin and telithromycin and a greater than thre

86 tions and zwitterions (viz., the antibiotics clarithromycin and tetracycline) to dissolved humic acid

87 ing ermB- versus mefE-mediated resistance to clarithromycin and to determine the relative frequency w

88 f atorvastatin, digoxin, and erythromycin or clarithromycin and was not significantly different for c

89 were randomized to 20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole twice a day for 1

90 crolide antibiotics, including erythromycin, clarithromycin, and azithromycin, are the mainstays of e

91 Macrolide antibiotics, like erythromycin, clarithromycin, and azithromycin, possess anti-inflammat

92 ntamicin, trimethoprim and sulfamethoxazole, clarithromycin, and azithromycin.

93 Resistance to metronidazole, clarithromycin, and levofloxacin is more common among H.

94 The prevalence of metronidazole, clarithromycin, and levofloxacin resistance varied by re

95 erapy); 5 days of lansoprazole, amoxicillin, clarithromycin, and metronidazole (concomitant therapy);

96 ential); or 5-day lansoprazole, amoxicillin, clarithromycin, and metronidazole (concomitant).

97 xicillin followed by 5 days of lansoprazole, clarithromycin, and metronidazole (sequential therapy).

98 amoxicillin followed by 5-day lansoprazole, clarithromycin, and metronidazole (sequential); or 5-day

99 ighly susceptible to all drugs tested except clarithromycin, and most clinical cases were successfull

100 mode) was found for amikacin, ciprofloxacin, clarithromycin, and moxifloxacin.

101 ults suggest that a combination of amikacin, clarithromycin, and rifabutin may be the most efficaciou

102 nically important antibiotics ciprofloxacin, clarithromycin, and rifampicin in the case of suspected

103 ilus influenzae to ampicillin, azithromycin, clarithromycin, and telithromycin was evaluated by alter

104 and 87 M. abscessus isolates), including 54 clarithromycin- and/or amikacin-resistant strains, were

105 h the total concentrations of azithromycin-, clarithromycin-, and erythromycin-related compounds reac

106 bitors are effective against metronidazole-, clarithromycin-, and rifampicin-resistant Hp clinical is

107 a proton-pump inhibitor plus amoxicillin and clarithromycin are significantly less effective for erad

108 Metronidazole and clarithromycin are the two key antibiotics.

109 , alone or in combination with rifampicin or clarithromycin, are promising candidates for treating ba

110 c bacterial infection in a mouse model using clarithromycin as a model antibiotic and Helicobacter py

111 Among 125 mefE(+) isolates, the MIC of clarithromycin at which 90% of the isolates tested were

112 sts and epithelial cells rapidly accumulated clarithromycin, attaining steady-state intracellular con

113 to 68%, 23%, and 10% decreases in C(max) of clarithromycin, azithromycin, and moxifloxacin.

114 MICs of erythromycin, clarithromycin, azithromycin, rifampin, gentamicin, and

115 tein (cyclosporine, ketoconazole, ritonavir, clarithromycin, azithromycin, verapamil ER [extended rel

116 Clarithromycin-based regimens are commonly used as a fir

117 Among 53 persons treated with clarithromycin-based regimens, treatment failed in 77% o

118 The eradication rate obtained with Clarithromycin-based sequential treatment was significan

119 ilar or greater eradication rate compared to clarithromycin-based therapy.

120 ociated with a greater risk for failure with clarithromycin-based treatments.

121 therapy for first-line treatment, replacing clarithromycin-based triple therapy.

122 fety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and de

123 ncluding the competitive effect of Ca(2+) on clarithromycin binding over a wide range of solution con

124 icosteroids, a long-acting beta agonist, and clarithromycin, but her condition did not improve and he

125 Clarithromycin can attain higher levels in gingiva than

126 Clarithromycin can attain higher levels in gingiva than

127 Moreover, genotypic resistance to clarithromycin can be predicted without obtaining a biop

128 This distribution profile of clarithromycin can thus be advantageous in the managemen

129 Finally, we evaluated the 3-drug combination clarithromycin, cefoxitin, and amikacin.

130 e range of MICs of several drugs, especially clarithromycin, ciprofloxacin, and sulfamethoxazole.

131 roton pump inhibitors (PPI), amoxicillin and clarithromycin (CLA) has been the standard in Latin Amer

132 treatment with a combination of ISS-ODN and clarithromycin (CLA) was tested in vitro and in vivo.

133 0 mg 2x/day, amoxicillin 1000 mg 12/12 h and clarithromycin (CLARI) 500 mg 12/12 h, for 14 days.

134 oxicillin + metronidazole (AMX + MET) versus clarithromycin (CLM) as adjuncts to one-stage full-mouth

135 tive effects of subgingivally delivered 0.5% clarithromycin (CLM) as an adjunct to scaling and root p

136 ic responses and possible adverse effects of clarithromycin (CLM) combined with periodontal mechanica

137 determined by Epsilometer test (E-test) for clarithromycin (CLR) and amoxicillin (AMX).

138 Results from this study indicate that a 1599 clarithromycin combination is potentially viable, provid

139 etronidazole, levofloxacin, tetracyclin, and clarithromycin, commonly used to treat H. pylori infecti

140 ed that the increased risk of CV events with clarithromycin compared with amoxicillin was associated

141 a calcium-channel blocker, concurrent use of clarithromycin compared with azithromycin was associated

142 These samples were analyzed for detection of clarithromycin concentration using high-performance liqu

143 Mean clarithromycin concentrations in healthy control and inf

144 after the last dose of clarithromycin, mean clarithromycin concentrations in serum and periodontal t

145 tations remains low in Marilia, the standard clarithromycin containing triple therapy is still valid.

146 oted unsatisfactory efficacy (ie, <80%) with clarithromycin-containing regimens in countries where th

147 Clarithromycin-containing regimens should be avoided in

148 The samples were extracted, and clarithromycin content was analyzed by liquid chromatogr

149 is further demonstrated in the synthesis of clarithromycin derivative, in which a tert-butyl ester i

150 Five of the 312 patients reportedly taking clarithromycin developed cryptosporidiosis vs 30 of the

151 Concentrations of carbendazim, clarithromycin, diclofenac, and diuron exceed levels of

152 st clinical isolates confirming synergy with Clarithromycin, Doxycycline and Clindamycin, combination

153 against amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline, imipenem, and trimethoprim-

154 against amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline, imipenem, sulfamethoxazole,

155 posaconazole; cyclosporine; erythromycin or clarithromycin; dronedarone; rifampin; or phenytoin.

156 valence of primary resistance of H.pylori to clarithromycin due to A2142G and A2143G mutations remain

157 PPI triple therapy (PPI + clarithromycin + either amoxicillin or metronidazole) is

158 nse to a three-times-weekly (TIW) regimen of clarithromycin, ethambutol, and rifampin.

159 For ibuprofen-clarithromycin-furosemide, the elimination profiles were

160 erapy with Levofloxacin 500 mg id instead of Clarithromycin (group B).

161 Clarithromycin had no detectable effect in either group.

162 ri-positive patients; however, resistance to clarithromycin has led to treatment failures.

163 ic modulators of GABA-A receptors, including clarithromycin, have been reported to reduce sleepiness

164 fference of 0.9 [95% CI, -1.6 to 3.3] in the clarithromycin-hydroxychloroquine group vs. the placebo

165 ne group, 35.6 (95% CI, 34.2 to 37.1) in the clarithromycin-hydroxychloroquine group, and 34.8 (95% C

166 patients in the doxycycline group, 96 in the clarithromycin-hydroxychloroquine group, and 98 in the p

167 isease or nonulcer dyspepsia); resistance to clarithromycin, imidazoles, or both; duration of triple

168 nd susceptible or intermediate to cefoxitin, clarithromycin, imipenem, and amikacin.

169 e tested once on three separate days against clarithromycin in 12B medium at pH 7.3 to 7.4 and agains

170 and undifferentiated HL-60 cells all took up clarithromycin in a saturable manner.

171 , being to our knowledge the first report of clarithromycin in edible fish muscle.

172 study determines the distribution profile of clarithromycin in the gingiva of patients with periodont

173 The odds of isolates being resistant to clarithromycin increased in relation to the number of co

174 an age 66 years, 47% male]), when prescribed clarithromycin, individuals with genetically determined

175 One variant, associated with clarithromycin-induced arrhythmia, increases channel blo

176 Clarithromycin inhibits several periodontal pathogens an

177 Clarithromycin interaction with dissolved humic acid was

178 Clarithromycin is a well-known antibiotic that exists in

179 Clarithromycin is an inhibitor of CYP3A4 and azithromyci

180 cobacterium isolates, extended incubation in clarithromycin is necessary to determine macrolide susce

181 t is not widely prescribed by periodontists, clarithromycin is potentially useful because it is taken

182 had H pylori strains that were resistant to clarithromycin (Italy, 26%; Spain, 19.5%), 33% were resi

183 e of alleles of 23S rRNA (A2142G/A2143G) for clarithromycin (kappa coefficient, 0.84; 95% confidence

184 The combination of clarithromycin, lenalidomide, and dexamethasone (BiRd) w

185 Clarithromycin levels at control and gingivitis sites we

186 At steady state, clarithromycin levels inside HL-60 granulocytes and PMNs

187 nflamed sites, so it is reasonable to expect clarithromycin levels to be higher in periodontally dise

188 By increasing intracellular clarithromycin levels, this system may enhance the effec

189 tions that are known to confer resistance to clarithromycin, levofloxacin, and tetracycline.

190 uccessful, it is likely due to resistance to clarithromycin, levofloxacin, and/or metronidazole; thes

191 Clarithromycin-loaded PMNs killed significantly more A.

192 e incubated at 37 degrees C with control and clarithromycin-loaded PMNs.

193 ronidazole < amoxicillin + clavulanic acid < clarithromycin < penicillin V < clindamycin.

194 nted for the testing of M. fortuitum against clarithromycin; M. abscessus and M. chelonae against the

195 ional studies are needed, this suggests that clarithromycin may be a reasonable treatment option in p

196 r fluid flow at control sites suggested that clarithromycin may produce anti-inflammatory effects.

197 xicillin, mean age 63 years, 56% male; 7,121 clarithromycin, mean age 66 years, 47% male]), when pres

198 rete antibiotic prescribing episodes (34,074 clarithromycin, mean age 73 years, 42% male; 171,153 amo

199 Approximately 6 hours after the last dose of clarithromycin, mean clarithromycin concentrations in se

200 e association with P-gp, a major pathway for clarithromycin metabolism.

201 a P-glycoprotein (P-gp), a major pathway for clarithromycin metabolism.

202 Only 13 of the 356 isolates had resistant clarithromycin MICs at initial extended MIC readings, an

203 with 23S rRNA gene mutations), 85 (24%) had clarithromycin MICs of </=8 mug/ml.

204 patients were prescribed oral azithromycin, clarithromycin, moxifloxacin, levofloxacin, ciprofloxaci

205 sers older than 65 years who were prescribed clarithromycin (n = 72,591) or erythromycin (n = 3267) c

206 n age, 76 years) who were newly coprescribed clarithromycin (n = 96,226) or azithromycin (n = 94,083)

207 ught to systematically assess the effects of clarithromycin on objective vigilance and subjective sle

208 vational cohort study of patients prescribed clarithromycin or amoxicillin in the community in Taysid

209 intermittent therapy (n = 118) that included clarithromycin or azithromycin, rifampin, and ethambutol

210 strains resistant to either metronidazole or clarithromycin or both.

211 No association was noted between clarithromycin or ciprofloxacin and adverse cardiac outc

212 Of those in whom clarithromycin or combination therapy failed, 29% and 27

213 zithromycin, coprescription of a statin with clarithromycin or erythromycin was associated with a hig

214 In older adults, coprescription of clarithromycin or erythromycin with a statin that is met

215 pump inhibitor or H2 receptor blockers, plus clarithromycin or metronidazole, plus amoxicillin or tet

216 ation rates were unaffected by resistance to clarithromycin or metronidazole.

217 ed in 9%, 15%, and 7% of those randomized to clarithromycin or rifabutin alone or in combination, res

218 the three injectable medications: amikacin, clarithromycin, or kanamycin, in addition to isoniazid a

219 ge fluid (repeated for RPMI 1640 medium with clarithromycin, other macrolides, and other gram-negativ

220 to demonstrate metronidazole (P < 0.05) and clarithromycin (P < 0.05) resistance.

221 ibitor [PPI] + amoxicillin + metronidazole + clarithromycin [PAMC]) and traditional bismuth quadruple

222 eceive a 12-week oral course of doxycycline, clarithromycin plus hydroxychloroquine, or placebo.

223 Both aiHp and resistance to clarithromycin proved to be highly significant (p<=0.001

224 Co-administration of 1599 and clarithromycin provided additional bacterial killing in

225 broad-spectrum antibiotics (azithromycin and clarithromycin, quinolones, amoxicillin-clavulanate, and

226 ow rate was evident at the conclusion of the clarithromycin regimen (P = 0.018).

227 idiosis vs 30 of the 707 patients not taking clarithromycin (relative hazard [RH], 0.25 [95% confiden

228 36.2% showed point mutations associated with clarithromycin resistance (A2142C, A2142G, A2143G).

229 expected gene deletion and showed inducible clarithromycin resistance after 14 days.

230 les likely permitted induction of phenotypic clarithromycin resistance and subsequent loss of synergi

231 e developed to assess inducible and acquired clarithromycin resistance and tested on a total of 90 cl

232 a rapid and accurate H.pylori diagnostic and clarithromycin resistance determination method useful fo

233 ated in isolates from 222/531 (42%) persons, clarithromycin resistance in 159/531 (30%) persons, amox

234 n from Santiago, and to establish the pooled clarithromycin resistance in Santiago, Chile.

235 Clarithromycin resistance is associated with a greater r

236 avoided in countries where the prevalence of clarithromycin resistance is higher than 20%.

237 of this study were to evaluate the effect of clarithromycin resistance on H. pylori eradication in a

238 azole) is restricted to areas with known low clarithromycin resistance or high eradication success wi

239 n-containing regimens in countries where the clarithromycin resistance rates were higher than 20%.

240 Phenotypic detection of clarithromycin resistance requires extended incubation (

241 s group, a multiplex real-time PCR assay for clarithromycin resistance showed 95% (38/40) concordance

242 The clarithromycin resistance suggested the presence of an i

243 MAG can display clarithromycin resistance through the inducible erm(41)

244 Clarithromycin resistance was determined upon analysis o

245 sitivity and specificity in the detection of clarithromycin resistance were 96.3% (52/54) and 100% (9

246 een isolates showed rrl mutations conferring clarithromycin resistance, including A2058G (11 isolates

247 Regarding clarithromycin resistance, NTM-DR detected rrl mutations

248 2C mutation potentially conferring low-level clarithromycin resistance, while levels of metronidazole

249 M. bolletii and the assessment of inducible clarithromycin resistance.

250 pylori isolates demonstrated a high invitro clarithromycin resistance.

251 V of the H. pylori 23S rDNA associated with clarithromycin resistance.

252 infection in an area with high prevalence of clarithromycin resistance.

253 Prevalence of H.pylori with clarithromycin resistant genotypes was 2,46%, with predo

254 ally due to emergency cases and increases of clarithromycin resistant strains.

255 in combination, were evaluated against both clarithromycin-resistant (CLR-R) and CLR-susceptible (CL

256 s, treatment failed in 77% of those carrying clarithromycin-resistant H. pylori (10 of 13) and 13% of

257 sponsible for community-acquired infections, clarithromycin-resistant Helicobacter pylori, and fluoro

258 ntified 51 patients over a 15-yr period with clarithromycin-resistant MAC (minimum inhibitory concent

259 Risk of MAC disease was reduced by 44% with clarithromycin (risk ratio [RR], 0.56; 95% CI, 0.37-0.84

260 mmatory activity of 3 macrolide antibiotics, clarithromycin, roxithromycin, and azithromycin, in an i

261 inary and human antimicrobials enrofloxacin, clarithromycin, roxithromycin, doxycycline and oxytetrac

262 bination therapy was not more effective than clarithromycin (RR, 0.79; 95% CI, 0.48-1.31; P=.36).

263 Twelve of 13 aiHp cases with a clarithromycin sensitive strain, who failed eradication,

264 of forty-seven H. pylori isolates cultured, clarithromycin sensitivity was present in 30(64%) and am

265 ral or parenteral macrolide (azithromycin or clarithromycin) served as the comparison group.

266 o: 14 days of lansoprazole, amoxicillin, and clarithromycin (standard therapy); 5 days of lansoprazol

267 We recommend that clarithromycin susceptibility breakpoints for M. abscess

268 resence of Helicobacter pylori and determine clarithromycin susceptibility in paraffin-embedded biops

269 Availability of PCR-based clarithromycin susceptibility test results from pre-trea

270 Clarithromycin susceptibility testing of MAC using the S

271 as Health Science Center at Tyler) underwent clarithromycin susceptibility testing with readings at 3

272 d, like M. chelonae, do not require extended clarithromycin susceptibility testing.

273 , respective values were 46.2% vs. 78.8%; in clarithromycin susceptible cases 60.6% vs. 91.9%.

274 t H. pylori (10 of 13) and 13% of those with clarithromycin-susceptible strains (5 of 40) (relative r

275 In contrast to clarithromycin, tetracycline binding to humic acid incre

276 but was the only side effect more common on clarithromycin than placebo.

277 At each site, strains were tested against clarithromycin three times on each of three separate day

278 s of resistance; susceptibility to amikacin, clarithromycin, tobramycin (only in M. chelonae), and ce

279 We assayed clarithromycin transport by measuring cell-associated ra

280 Clarithromycin transport exhibited Michaelis-Menten kine

281 Clarithromycin transport was assayed by measuring change

282 roups: 14-day lansoprazole, amoxicillin, and clarithromycin (triple therapy); 5-day lansoprazole and

283 pantoprazole, 1000 mg amoxicillin and 500 mg clarithromycin, twice daily for 7 days; iDU sequential t

284 ne and 3 days after administration of 500 mg clarithromycin, twice daily, for 3 days.

285 study was to characterize the mechanisms of clarithromycin uptake by gingival fibroblasts and oral e

286 Clarithromycin use was significantly associated with inc

287 s (HRs) adjusted for likelihood of receiving clarithromycin using inverse proportion of treatment wei

288 to examine CV risk following prescription of clarithromycin versus amoxicillin and in particular, the

289 CV hospitalization following prescription of clarithromycin versus amoxicillin at 0-14 days, 15-30 da

290 companion drugs, with no risk difference in clarithromycin versus azithromycin and daily versus inte

291 of sleepiness were significantly improved on clarithromycin versus placebo.

292 Thus, both types of cells take up clarithromycin via a concentrative active transport syst

293 Coprescribing clarithromycin vs azithromycin with a calcium-channel bl

294 therapy using omeprazole, metronidazole, and clarithromycin was administered p.o. at 8, 12, or 22 WPI

295 Coprescription with clarithromycin was also associated with a higher risk of

296 Resistance to clarithromycin was associated with previous use of any m

297 with constitutive resistance to amikacin and clarithromycin were isolated from several individuals ne

298 c acid, cefdinir, cefixime, ceftriaxone, and clarithromycin were the most reproducible.

299 HL-60 granulocytes transported clarithromycin with a K(m) of approximately 250 mug/ml a

300 the association of the macrolide antibiotic clarithromycin with cardiovascular (CV) events.

301 Incubation in medium containing 2 mug/mL clarithromycin yielded steady-state intracellular concen